查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965842

肌鈣蛋白市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Troponin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肌鈣蛋白市場預計將從 2025 年的 21.2 億美元成長到 2031 年的 32.1 億美元，複合年成長率為 7.16%。

該市場以肌鈣蛋白I和肌鈣蛋白T的診斷需求為特徵，這兩種蛋白是肌肉收縮和功能所必需的特定調節蛋白，也是識別心肌損傷的關鍵生物標記。推動市場成長的根本因素是急性冠狀動脈症候群率的上升以及對胸痛患者進行快速風險分層的重要性。此外，全球人口老化自然會增加心臟事件的風險，這也支撐了對這些診斷測試的需求。根據美國心臟協會（AHA）的數據，到2024年，約有1.269億美國人（幾乎佔成年人口的一半）將受到某種形式的心血管疾病的影響，這將造成沉重的疾病負擔，需要頻繁且準確的檢測。這些因素鞏固了該市場的成長動能。

市場概覽
預測期 2027-2031
市場規模：2025年 21.2億美元
市場規模：2031年 32.1億美元
複合年成長率：2026-2031年 7.16%
成長最快的細分市場 肌鈣蛋白 I
最大的市場 北美洲

然而，在存在基礎疾病的患者中，分析特異性方面存在顯著的市場擴張障礙。肌鈣蛋白水平升高常見於非急性急性冠狀動脈症候群症候群，例如敗血症和慢性腎臟病，導致診斷模糊不清。這種陽性的可能性使臨床決策複雜化，並常常迫使醫護人員進行昂貴的額外檢查以排除其他疾病。因此，醫療資源緊張，非心臟原因的適當治療可能被延誤，標準診斷流程的效率也受到挑戰。

市場促進因素

全球心血管疾病和心肌梗塞發病率的不斷上升是全球肌鈣蛋白市場的主要驅動力。由於心臟病仍然是全球主要死因之一，因此迫切需要利用肌鈣蛋白I和T等快速生物標記來加速早期診斷和介入。日益加重的疾病負擔確保了急診和重症監護環境中對診斷檢測的高需求。根據世界衛生組織（世衛組織）2025年7月的情況說明書，預計每年將有1,980萬人死於心血管疾病，凸顯了有效檢測工具的迫切需求。這種需求推動了相關人員的強勁財務表現；例如，羅氏2024年的財務報告顯示，其診斷部門的銷售額為143億瑞士法郎，這主要得益於包括心臟檢測在內的免疫診斷解決方案的強勁成長勢頭。

高靈敏度肌鈣蛋白檢測技術的進步，透過提高診斷準確性和拓展臨床應用範圍，進一步加速了市場成長。該行業正從標準檢測轉向能夠檢測更低濃度肌鈣蛋白的高靈敏度檢測，使臨床醫生能夠更快地排除心肌梗塞，並更有把握地評估長期風險。這些創新正在創造附加價值，使檢測手段從簡單的診斷發展到預測性分析。根據《醫學實驗室觀察》（Medical Laboratory Observer）2025年1月報道，美國食品藥物管理局（FDA）核准西門子醫療的Atellica IM高靈敏度肌鈣蛋白I血液檢測，用於預測長達365天的重大心臟事件。這些進步正在改善患者分層，縮短住院時間，並加速醫療機構的普及應用。

市場挑戰

全球肌鈣蛋白市場擴張的一大障礙是合併症患者的分析特異性問題。在慢性腎臟病等非急性疾病患者中，肌鈣蛋白水平常常升高，而與急性心肌梗塞無關，這造成了診斷上的不確定性。這使得臨床醫師難以僅憑生物標記證據快速確診心肌梗塞。在這些複雜病例中，無法僅依賴肌鈣蛋白檢測結果，迫使醫療機構進行額外的、耗費資源的確認性檢測。這增加了醫療成本，削弱了肌鈣蛋白檢測作為快速、獨立診斷工具的提案，並阻礙了其在注重成本的醫療環境中的廣泛應用。

合併症的普遍存在進一步加劇了這項挑戰。根據美國腎臟基金會估計，到2025年，將有3,550萬美國人患有慢性腎臟病，這構成了一個龐大的患者群體，而對他們來說，標準的肌鈣蛋白檢測結果往往並不明確。如此大規模的患者族群中假陽性率較高，迫使醫療機構採取謹慎的檢測通訊協定。這實際上限制了該檢測方法在需要精確心臟監測的關鍵患者群體中的效用，從而抑制了市場成長潛力。

市場趨勢

即時檢測（POC​​）心臟檢測解決方案的普及正在重塑市場格局，將診斷能力從中心檢查室分散到更靠近患者的環境中。這項轉變的根本驅動力在於急診對更快檢測結果的需求以及基層醫療對檢測可及性的日益成長，促使主要行業參與者收購多功能快速檢測平台，以搶佔床邊檢測市場。這種對分散式診斷的策略優先考慮，體現在企業投入大量資金收購成熟的POC技術上。例如，羅氏於2024年7月完成了對Lumira Dx照護現場技術的收購，交易金額高達3.5億美元，透過整合其創新的多重檢測平台，直接強化了其全球分散式診斷策略。

同時，人工智慧（AI）在心臟診斷中的應用正在革新肌鈣蛋白水平的解讀方式，尤其是在最佳化快速陽性和陰性檢測通訊協定。人工智慧演算法結合高靈敏度檢測方法，能夠分析複雜的生物標記動態變化，從而比標準指南更有效地解決低風險症狀患者的診斷難題。這種數位工具與生物鑑定的協同作用顯著提高了分流速度，並減少了不必要的住院。德國心血管研究中心（DZHK）2024年8月發布的報告顯示，一種新的機器學習輔助方法可以排除約35%患者的心肌梗塞－這一比例是傳統診斷方法的兩倍以上。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肌鈣蛋白市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（肌鈣蛋白 I、肌鈣蛋白 T、肌鈣蛋白複合物、其他）
    • 依應用領域（心肌梗塞、急性冠狀動脈症候群、鬱血性心臟衰竭、心肌病等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肌鈣蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肌鈣蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肌鈣蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肌鈣蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美肌鈣蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肌鈣蛋白市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Mitsubishi Chemical Group Corporation
  • QuidelOrtho Corporation
  • Getein Biotech, Inc.
  • Bio-Rad Laboratories, Inc.
  • Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24596

The Global Troponin Market is projected to expand from USD 2.12 Billion in 2025 to USD 3.21 Billion by 2031, registering a CAGR of 7.16%. This market is characterized by the diagnostic necessity for specific regulatory proteins, Troponin I and Troponin T, which are essential for muscle contraction and serve as the primary biomarkers for identifying myocardial damage. Growth is fundamentally driven by the rising incidence of acute coronary syndromes and the critical requirement for rapid risk stratification in patients experiencing chest pain. Furthermore, the aging global population, which is naturally more prone to cardiac events, sustains demand for these diagnostic tests. Data from the American Heart Association indicates that in 2024, approximately 126.9 million Americans-nearly half the adult population-were affected by some form of cardiovascular disease, creating a heavy disease burden that necessitates frequent, accurate testing and secures the market's trajectory.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.12 Billion
Market Size 2031USD 3.21 Billion
CAGR 2026-20317.16%
Fastest Growing SegmentTroponin I
Largest MarketNorth America

However, market expansion faces a significant obstacle regarding analytical specificity in patients with underlying comorbidities. Elevated troponin levels often occur in non-acute coronary syndrome conditions, such as sepsis or chronic kidney disease, resulting in diagnostic ambiguity. This potential for false positives complicates clinical decision-making and frequently compels healthcare providers to conduct expensive, supplementary testing to rule out other pathologies. Consequently, this strains healthcare resources and may delay appropriate treatments for non-cardiac causes, thereby challenging the efficiency of standard diagnostic workflows.

Market Driver

The increasing global prevalence of cardiovascular diseases and myocardial infarction acts as the primary catalyst for the Global Troponin Market. With heart conditions remaining the leading cause of mortality worldwide, there is an urgent demand for rapid biomarkers like troponin I and T to facilitate early diagnosis and intervention. This escalating disease burden ensures high-volume demand for diagnostic testing in emergency and critical care settings. According to the World Health Organization's July 2025 facts sheet, cardiovascular diseases claim an estimated 19.8 million lives annually, highlighting the critical need for effective detection tools. This demand translates into strong financial performance for key stakeholders; for instance, Roche's 2024 Finance Report noted that its Diagnostics Division achieved 14.3 billion Swiss francs in sales, driven significantly by the momentum of immunodiagnostic solutions, including cardiac testing.

Technological advancements in high-sensitivity troponin assays are further propelling market growth by enhancing diagnostic precision and broadening clinical applications. The industry is shifting from standard assays to high-sensitivity versions capable of detecting significantly lower troponin levels, enabling clinicians to rule out myocardial infarction more quickly and assess long-term risks with greater confidence. These innovations add value by moving beyond simple diagnosis to predictive analytics. As reported by Medical Laboratory Observer in January 2025, the FDA cleared Siemens Healthineers' Atellica IM High-Sensitivity Troponin I blood test to help predict major cardiac events for up to 365 days. Such advancements reduce hospital stays and improve patient stratification, driving widespread adoption across healthcare facilities.

Market Challenge

A major barrier to the expansion of the Global Troponin Market is the issue of analytical specificity in patients with comorbidities. When patients present with non-acute conditions such as chronic kidney disease, troponin levels often rise independently of acute myocardial infarction, creating diagnostic ambiguity. This makes it difficult for clinicians to rapidly confirm a heart attack based solely on biomarker evidence. The inability to rely exclusively on troponin results in these complex cases forces healthcare facilities to implement additional, resource-intensive confirmatory tests. This requirement inflates healthcare costs and undermines the value proposition of troponin assays as rapid, standalone diagnostic tools, thereby slowing their broader adoption in cost-sensitive medical environments.

This challenge is magnified by the widespread prevalence of confounding conditions. According to the American Kidney Fund, in 2025, an estimated 35.5 million Americans were living with chronic kidney disease, representing a significant patient demographic where standard troponin results are frequently inconclusive. The high probability of false positives in such a large population subset compels medical institutions to maintain cautious testing protocols. This effectively restricts the market's growth potential by limiting the utility of the test for a major category of patients who otherwise require accurate cardiac monitoring.

Market Trends

The proliferation of Point-of-Care (POC) cardiac testing solutions is reshaping the market by decentralizing diagnostic capabilities from central laboratories to near-patient settings. This shift is fundamentally driven by the need to reduce turnaround times in emergency departments and expand access in primary care, prompting major industry players to acquire versatile, rapid testing platforms to capture the bedside testing segment. This strategic prioritization of decentralized diagnostics is evidenced by significant corporate capital allocation toward acquiring established POC technologies. For instance, Roche completed a transaction valued at up to USD 350 million in July 2024 to acquire LumiraDx's Point of Care technology, integrating an innovative multi-assay platform to directly reinforce its global decentralized diagnostic strategy.

Simultaneously, the integration of Artificial Intelligence in cardiac diagnostics is revolutionizing how troponin levels are interpreted, specifically to optimize rapid rule-in and rule-out protocols. AI algorithms are increasingly being paired with high-sensitivity assays to analyze complex biomarker kinetics, thereby resolving diagnostic ambiguity in patients with low-risk presentations more efficiently than standard guidelines. This synergy between digital tools and biological assays significantly enhances triage speed and reduces unnecessary hospitalizations. According to the German Centre for Cardiovascular Research (DZHK) in August 2024, a new machine-learning supported approach demonstrated the ability to rule out myocardial infarction in approximately 35% of patients, more than double the rate achieved by conventional diagnostic procedures.

Key Market Players

  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Mitsubishi Chemical Group Corporation
  • QuidelOrtho Corporation
  • Getein Biotech, Inc.
  • Bio-Rad Laboratories, Inc.
  • Merck KGaA

Report Scope

In this report, the Global Troponin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Troponin Market, By Type

  • Troponin I
  • Troponin T
  • Troponin Complex
  • Others

Troponin Market, By Application

  • Myocardial Infarction
  • Acute Coronary Syndrome
  • Congestive Heart Failure
  • Cardiomyopathy
  • Others

Troponin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Troponin Market.

Available Customizations:

Global Troponin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Troponin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Troponin I, Troponin T, Troponin Complex, Others)
    • 5.2.2. By Application (Myocardial Infarction, Acute Coronary Syndrome, Congestive Heart Failure, Cardiomyopathy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Troponin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Troponin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Troponin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Troponin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Troponin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Troponin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Troponin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Troponin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Troponin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Troponin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Troponin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Troponin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Troponin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Troponin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Troponin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Troponin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Troponin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Troponin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Troponin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Troponin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Troponin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Troponin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Troponin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Troponin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Troponin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd
  • 15.3. Siemens Healthineers AG
  • 15.4. Beckman Coulter, Inc.
  • 15.5. bioMerieux SA
  • 15.6. Mitsubishi Chemical Group Corporation
  • 15.7. QuidelOrtho Corporation
  • 15.8. Getein Biotech, Inc.
  • 15.9. Bio-Rad Laboratories, Inc.
  • 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer